Literature DB >> 31002391

Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen.

Stephen A Greene1,2, Jingxian Chen1,3, Heather M A Prince4, Craig Sykes1, Amanda P Schauer1, Kimberly Blake1, Julie A E Nelson5, Cynthia L Gay4, Myron S Cohen4, Julie B Dumond1.   

Abstract

Understanding antiretroviral disposition in the male genital tract, a distinct viral compartment, can provide insight for the eradication of HIV. Population pharmacokinetic modeling was conducted to investigate the disposition of tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and emtricitabine and their metabolites in blood and semen. Blood plasma and seminal plasma (SP) concentrations of tenofovir and emtricitabine were measured, as were tenofovir-diphosphate and emtricitabine-triphosphate concentrations in peripheral blood mononuclear cells (PBMCs) and seminal mononuclear cells. Sequential compartmental modeling described drug disposition in blood and semen. Our modeling suggests slower elimination of apparent tenofovir-diphosphate PBMC and faster elimination of tenofovir SP after administration of TAF compared with TDF, likely reflecting flip-flop kinetics. Additionally, TAF metabolism to tenofovir appeared slower in semen compared with blood; however, SP elimination of TAF-derived tenofovir appeared faster than its blood plasma elimination. These findings provide valuable insight for further mechanistic study of cellular entry and drug metabolism in the male genital tract.
© 2019 The Authors Clinical Pharmacology & Therapeutics © 2019 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31002391      PMCID: PMC7079728          DOI: 10.1002/cpt.1464

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  30 in total

1.  Ways to fit a PK model with some data below the quantification limit.

Authors:  S L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

2.  Handling data below the limit of quantification in mixed effect models.

Authors:  Martin Bergstrand; Mats O Karlsson
Journal:  AAPS J       Date:  2009-05-19       Impact factor: 4.009

3.  A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.

Authors:  Mackenzie L Cottrell; Kuo H Yang; Heather M A Prince; Craig Sykes; Nicole White; Stephanie Malone; Evan S Dellon; Ryan D Madanick; Nicholas J Shaheen; Michael G Hudgens; Jacob Wulff; Kristine B Patterson; Julie A E Nelson; Angela D M Kashuba
Journal:  J Infect Dis       Date:  2016-02-24       Impact factor: 5.226

4.  Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations.

Authors:  Marco Simiele; Antonio D'Avolio; Lorena Baietto; Marco Siccardi; Mauro Sciandra; Silvia Agati; Jessica Cusato; Stefano Bonora; Giovanni Di Perri
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

5.  Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.

Authors:  Peter J Ruane; Edwin DeJesus; Daniel Berger; Martin Markowitz; U Fritz Bredeek; Christian Callebaut; Lijie Zhong; Srini Ramanathan; Martin S Rhee; Marshall W Fordyce; Kitty Yale
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-01       Impact factor: 3.731

Review 6.  The role of latency reversal agents in the cure of HIV: A review of current data.

Authors:  Kiandokht Bashiri; Nima Rezaei; Milena Nasi; Andrea Cossarizza
Journal:  Immunol Lett       Date:  2018-02-07       Impact factor: 3.685

7.  Single- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men.

Authors:  Kevin C Brown; Kristine B Patterson; Steven H Jennings; Stephanie A Malone; Nicholas J Shaheen; Heather M Asher Prince; Melissa Spacek; Myron S Cohen; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2012-10-01       Impact factor: 3.731

Review 8.  Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.

Authors:  Adrian S Ray; Marshall W Fordyce; Michael J M Hitchcock
Journal:  Antiviral Res       Date:  2015-11-27       Impact factor: 5.970

9.  Basolateral uptake of nucleosides by Sertoli cells is mediated primarily by equilibrative nucleoside transporter 1.

Authors:  David M Klein; Kristen K Evans; Rhiannon N Hardwick; William H Dantzler; Stephen H Wright; Nathan J Cherrington
Journal:  J Pharmacol Exp Ther       Date:  2013-05-02       Impact factor: 4.030

10.  Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women.

Authors:  Rebecca N Burns; Craig W Hendrix; Ayyappa Chaturvedula
Journal:  J Clin Pharmacol       Date:  2015-02-04       Impact factor: 3.126

View more
  3 in total

1.  Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women.

Authors:  Asama Tanaudommongkon; Ayyappa Chaturvedula; Craig W Hendrix; Edward J Fuchs; Eugenie Shieh; Rahul P Bakshi; Mark A Marzinke
Journal:  Br J Clin Pharmacol       Date:  2022-03-25       Impact factor: 3.716

2.  Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate.

Authors:  Ahizechukwu C Eke; Kensuke Shoji; Brookie M Best; Jeremiah D Momper; Alice M Stek; Tim R Cressey; Mark Mirochnick; Edmund V Capparelli
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.938

Review 3.  Tenofovir alafenamide use in pregnant and lactating women living with HIV.

Authors:  Ahizechukwu C Eke; Kristina M Brooks; Rahel D Gebreyohannes; Jeanne S Sheffield; Kelly E Dooley; Mark Mirochnick
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-03-17       Impact factor: 4.936

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.